Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1982 4
1983 4
1984 4
1985 3
1986 15
1987 15
1988 13
1989 10
1990 30
1991 45
1992 33
1993 69
1994 76
1995 74
1996 90
1997 94
1998 84
1999 135
2000 159
2001 183
2002 218
2003 273
2004 270
2005 287
2006 248
2007 290
2008 302
2009 288
2010 346
2011 361
2012 347
2013 323
2014 348
2015 360
2016 303
2017 286
2018 277
2019 277
2020 324
2021 305
2022 270
2023 221
2024 106

Text availability

Article attribute

Article type

Publication date

Search Results

6,801 results

Results by year

Filters applied: . Clear all
Page 1
Oral fludarabine.
Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(21):2317-23. doi: 10.2165/00003495-200363210-00004. Drugs. 2003. PMID: 14524733 Review.
Fludarabine is an antimetabolite antineoplastic agent used in the treatment of various haematological malignancies, particularly B-cell chronic lymphocytic leukaemia (CLL). ...These results were similar to the 48% overall response rate reported in a similar historical cont …
Fludarabine is an antimetabolite antineoplastic agent used in the treatment of various haematological malignancies, particularly B-ce …
Fludarabine: a review.
Hood MA, Finley RS. Hood MA, et al. DICP. 1991 May;25(5):518-24. doi: 10.1177/106002809102500512. DICP. 1991. PMID: 2068837 Review.
The new fluorinated adenine analog, fludarabine, has been tested for efficacy in many tumor types over the past ten years. ...Cytarabine is used principally as an antileukemic agent, and vidarabine as an antiviral. Unlike vidarabine, fludarabine is resistant to deac …
The new fluorinated adenine analog, fludarabine, has been tested for efficacy in many tumor types over the past ten years. ...Cytarab …
Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Green S, Schultz L. Green S, et al. Curr Oncol Rep. 2023 Aug;25(8):841-846. doi: 10.1007/s11912-023-01404-6. Epub 2023 Apr 26. Curr Oncol Rep. 2023. PMID: 37099243 Review.
In the context of a global fludarabine shortage, consideration of alternative regimens is timely, yet limited clinical data exists, specifically in the pediatric B-ALL CAR setting. ...We review the experience using bendamustine and clofarabine to serve as a resource when c …
In the context of a global fludarabine shortage, consideration of alternative regimens is timely, yet limited clinical data exists, s …
Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V, Choquet S. Leblond V, et al. Semin Oncol. 2003 Apr;30(2):239-42. doi: 10.1053/sonc.2003.50040. Semin Oncol. 2003. PMID: 12720144 Review.
Response rates to fludarabine in previously treated patients range from 30% to 50% and are highest among patients who are still sensitive to their primary therapy. The responses last from 32 to 41 months. The principal toxicity of fludarabine is myelosuppression. Tr …
Response rates to fludarabine in previously treated patients range from 30% to 50% and are highest among patients who are still sensi …
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, Algeri M, Yesilipek A, de la Fuente J, Isgrò A, Alseraihy A, Angelucci E, Smiers FJ, La La Nasa G, Zecca M, Fisgin T, Unal E, Kleinschmidt K, Peters C, Lankester A, Corbacioglu S; EBMT Pediatric Diseases, Inborn Errors Working Parties. Lüftinger R, et al. Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9. Ann Hematol. 2022. PMID: 34999929
The aim of this retrospective analysis was to investigate the role of busulfan-fludarabine-based and treosulfan-fludarabine-based conditioning in TDT patients undergoing HSCT. ...Two-year overall survival was 92.7% (95% confidence interval: 89.3-95.1%) after busulfa …
The aim of this retrospective analysis was to investigate the role of busulfan-fludarabine-based and treosulfan-fludarabine-ba …
Fludarabine and neurotoxicity in engineered T-cell therapy.
Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Lowe KL, et al. Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7. Gene Ther. 2018. PMID: 29789639
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cerebral edema. However, subsequent deaths in the JCAR-015 study after removal of fludarabine and improved understanding behind the mech …
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cer …
Fludarabine in chronic lymphocytic leukaemia.
Elter T, Hallek M, Engert A. Elter T, et al. Expert Opin Pharmacother. 2006 Aug;7(12):1641-51. doi: 10.1517/14656566.7.12.1641. Expert Opin Pharmacother. 2006. PMID: 16872267 Review.
Since the 1980s, fludarabine monotherapy has demonstrated an improvement in response over historical chemotherapeutic agents. ...A review of the fludarabine literature shows that these advancements in fludarabine-containing therapy have enhanced the overall p …
Since the 1980s, fludarabine monotherapy has demonstrated an improvement in response over historical chemotherapeutic agents. ...A re …
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Adkins JC, Peters DH, Markham A. Adkins JC, et al. Drugs. 1997 Jun;53(6):1005-37. doi: 10.2165/00003495-199753060-00007. Drugs. 1997. PMID: 9179529 Review.
In addition, sequential therapy with fludarabine and cytarabine has demonstrated good efficacy in the treatment of acute leukaemias, as has fludarabine monotherapy and combination therapy in low grade non-Hodgkin's lymphoma. ...Alopecia and nausea/vomiting appear to …
In addition, sequential therapy with fludarabine and cytarabine has demonstrated good efficacy in the treatment of acute leukaemias, …
Fludarabine: a review of the clear benefits and potential harms.
Lukenbill J, Kalaycio M. Lukenbill J, et al. Leuk Res. 2013 Sep;37(9):986-94. doi: 10.1016/j.leukres.2013.05.004. Epub 2013 Jun 17. Leuk Res. 2013. PMID: 23787174 Review.
BACKGROUND: Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppression and other toxicities. ...Fludarabine also causes potentially irreversible grade 3 or 4 cytopenias and infection in the majority …
BACKGROUND: Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppres …
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D, Husnain M, Khurana S, Simpson RJ, Katsanis E. Filioglou D, et al. Front Immunol. 2023 Nov 22;14:1329850. doi: 10.3389/fimmu.2023.1329850. eCollection 2023. Front Immunol. 2023. PMID: 38077398 Free PMC article. Review.
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in combination with fludarabine (Flu) (CY-FLU). While cyclophosphamide (CY) possesses lymphotoxic effects, it concurrently preserves regulat …
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in comb …
6,801 results

Searches related to "fludarabine"